Cargando…

A Dual-Type L2 11-88 Peptide from HPV Types 16/18 Formulated in Montanide ISA 720 Induced Strong and Balanced Th1/Th2 Immune Responses, Associated with High Titers of Broad Spectrum Cross-Reactive Antibodies in Vaccinated Mice

E. coli-derived concatenated, multitype L2-conserved epitopes of human papillomavirus (HPV) L2 protein might represent a less expensive and pan-type vaccine alternative (compared to type-specific HPV L1 virus-like particles), if stable protein expression and strong immunogenicity features could be m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Motavalli Khiavi, Farhad, Arashkia, Arash, Golkar, Majid, Nasimi, Maryam, Roohvand, Farzin, Azadmanesh, Kayhan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960516/ https://www.ncbi.nlm.nih.gov/pubmed/29854852 http://dx.doi.org/10.1155/2018/9464186

Ejemplares similares

Immunization of mice by a multimeric L2-based linear epitope (17-36) from HPV type 16/18 induced cross reactive neutralizing antibodies
por: Khiavi, Farhad Motavalli, et al.
Publicado: (2017)

Safety data of Montanide ISA 51 VG and Montanide ISA 720 VG, two adjuvants dedicated to human therapeutic vaccines
por: Ascarateil, Stephane, et al.
Publicado: (2015)

Sustained release of actives with Montanide™ ISA 51 VG and Montanide™ ISA 720 VG, two adjuvants dedicated to human therapeutic vaccines
por: Ascarateil, Stephane, et al.
Publicado: (2015)

Immune System Modulation by the Adjuvants Poly (I:C) and Montanide ISA 720
por: Marques, Rodolfo F., et al.
Publicado: (2022)

Cancer Vaccination against Extracellular Vimentin Efficiently Adjuvanted with Montanide ISA 720/CpG
por: van Loon, Karlijn, et al.
Publicado: (2022)

Isolation, cloning, and expression of E. coli BirA gene for biotinylation applications
por: Etemadzadeh, Mohammad Hossein, et al.
Publicado: (2015)

Adenovirus vector-based vaccines as forefront approaches in fighting the battle against flaviviruses
por: Shoushtari, Mohammad, et al.
Publicado: (2022)

Evaluation of Four Adjuvant Combinations, IVAX-1, IVAX-2, CpG-1826+Montanide ISA 720 VG and CpG-1018+Montanide ISA 720 VG, for Safety and for Their Ability to Elicit Protective Immune Responses in Mice against a Respiratory Challenge with Chlamydia muridarum
por: Pal, Sukumar, et al.
Publicado: (2023)

Safety and Immunogenicity of a Recombinant Plasmodium falciparum AMA1 Malaria Vaccine Adjuvanted with Alhydrogel™, Montanide ISA 720 or AS02
por: Roestenberg, Meta, et al.
Publicado: (2008)

Modulation of Antibody Responses against Gnathostoma spinigerum in Mice Immunized with Crude Antigen Formulated in CpG Oligonucleotide and Montanide ISA720
por: Intapan, Pewpan M., et al.
Publicado: (2013)

Expression of a biotin acceptor peptide-containing protein with potential incorporation on the lentiviral envelope as a viral surface engineering platform
por: Etemadzadeh, Mohammad Hossein, et al.
Publicado: (2015)

Safety and Immunogenicity of a Malaria Vaccine, Plasmodium falciparum AMA-1/MSP-1 Chimeric Protein Formulated in Montanide ISA 720 in Healthy Adults
por: Hu, Jinhong, et al.
Publicado: (2008)

A vaccine consisting of Schistosoma mansoni cathepsin B formulated in Montanide ISA 720 VG induces high level protection against murine schistosomiasis
por: Ricciardi, Alessandra, et al.
Publicado: (2016)

A Phase 1 Trial of MSP2-C1, a Blood-Stage Malaria Vaccine Containing 2 Isoforms of MSP2 Formulated with Montanide® ISA 720
por: McCarthy, James S., et al.
Publicado: (2011)

LigA formulated in AS04 or Montanide ISA720VG induced superior immune response compared to alum, which correlated to protective efficacy in a hamster model of leptospirosis
por: Varma, Vivek P., et al.
Publicado: (2022)

Modifying oncolytic virotherapy to overcome the barrier of the hypoxic tumor microenvironment. Where do we stand?
por: Shayan, Sara, et al.
Publicado: (2022)

Evaluation of Montanide™ ISA 71 VG Adjuvant during Profilin Vaccination against Experimental Coccidiosis
por: Jang, Seung I., et al.
Publicado: (2013)

Construction of Various γ34.5 Deleted Fluorescent-Expressing Oncolytic herpes Simplex type 1 (oHSV) for Generation and Isolation of HSV-Based Vectors
por: Abdoli, Shahriyar, et al.
Publicado: (2017)

In silico Identification of Hypoxic Signature followed by reverse transcription-quantitative PCR Validation in Cancer Cell Lines
por: Shayan, Sara, et al.
Publicado: (2023)

Cell type-specific response of colon cancer tumor cell lines to oncolytic HSV-1 virotherapy in hypoxia
por: Shayan, Sara, et al.
Publicado: (2022)

Immunization with Cocktail of HIV-Derived Peptides in Montanide ISA-51 Is Immunogenic, but Causes Sterile Abscesses and Unacceptable Reactogenicity
por: Graham, Barney S., et al.
Publicado: (2010)

IFN-α(2b) reduces released particles of Human T-lymphotropic Virus-I from HTLV-I transformed cell line
por: Hartoonian, Christine, et al.
Publicado: (2011)

The β‐domain of streptokinase affects several functionalities, including specific/proteolytic activity kinetics
por: Rafipour, Maryam, et al.
Publicado: (2019)

Contribution of Streptokinase-Domains from Groups G and A (SK2a) Streptococci in Amidolytic/Proteolytic Activities and Fibrin-Dependent Plasminogen Activation: A Domain-Exchange Study
por: Rafipour, Maryam, et al.
Publicado: (2020)

Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51
por: Wu, Yimin, et al.
Publicado: (2008)

A novel bivalent Pasteurellosis-RHD vaccine candidate adjuvanted with Montanide ISA70 protects rabbits from lethal challenge
por: El-Jakee, Jakeen K., et al.
Publicado: (2020)

Formulation of HBs antigen in Montanide ISA266 shows superiority to commercial HBsAg vaccine in the induction of humoral immune responses
por: Savoji, Mohammad Ali, et al.
Publicado: (2019)

Efficacy of SAT2 Foot-and-Mouth Disease Vaccines Formulated with Montanide ISA 206B and Quil-A Saponin Adjuvants
por: Rathogwa, Ntungufhadzeni M., et al.
Publicado: (2021)

Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909
por: Kuball, Jürgen, et al.
Publicado: (2010)

Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HT™ and Montanide ISA 51 in rhesus macaques
por: Kusi, Kwadwo A, et al.
Publicado: (2011)

Alum and a TLR7 agonist combined with built-in TLR4 and 5 agonists synergistically enhance immune responses against HPV RG1 epitope
por: Mashhadi Abolghasem Shirazi, Maryam, et al.
Publicado: (2023)

Development of a hexavalent recombinant protein vaccine adjuvanted with Montanide ISA 50 V and determination of its protective efficacy against acute toxoplasmosis
por: Şahar, Esra Atalay, et al.
Publicado: (2020)

Fiber manipulation and post-assembly nanobody conjugation for adenoviral vector retargeting through SpyTag-SpyCatcher protein ligation
por: Kadkhodazadeh, Maryam, et al.
Publicado: (2022)

Preface for the special issue of the 54th international congress of the ISAE
por: Campbell, Dana L.M., et al.
Publicado: (2023)

Recombinant hemagglutinin of swine H1N1 influenza virus expression in the insect cells: Formulation in Montanide ISA71 adjuvant and the potency studies
por: Zahmati, Sara, et al.
Publicado: (2021)

The Inclusive Review on SARS-CoV-2 Biology, Epidemiology, Diagnosis, and Potential Management Options
por: Beig Parikhani, Arezoo, et al.
Publicado: (2021)

88th SPSC Meeting
Publicado: (2008)

88th WE-Heraeus-Seminar
por: Schmidt, Rüdiger, et al.
Publicado: (1992)

88th Plenary ECFA meeting
Publicado: (2010)

On the Diseases of the 88th Regiment in Bombay
por: M'Gregor, James
Publicado: (1805)

Cannot write session to /tmp/vufind_sessions/sess_ggkevpia1ldf2b6sfqn3m1e5po